AGENUS INC Variable Lease, Cost
AGENUS INC (AGEN) reported Variable Lease, Cost of $2.78 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-16
- AGENUS INC variable lease, cost for the quarter ending 2020-12-31 was $353.00K, a 1.44% increase year-over-year.
- AGENUS INC variable lease, cost for the quarter ending 2020-09-30 was $525.00K, a 27.74% increase year-over-year.
- AGENUS INC variable lease, cost for the quarter ending 2020-06-30 was $495.00K, a 38.66% increase year-over-year.
- AGENUS INC variable lease, cost for the quarter ending 2020-03-31 was $513.00K, a 218.63% increase year-over-year.
- AGENUS INC variable lease, cost for fiscal 2025 was $2.78M, a 19.90% decline from fiscal 2024.
- AGENUS INC variable lease, cost for fiscal 2024 was $3.47M, a 2.73% increase from fiscal 2023.
- AGENUS INC variable lease, cost for fiscal 2023 was $3.38M, a 8.59% increase from fiscal 2022.
- AGENUS INC variable lease, cost for fiscal 2022 was $3.11M, a 70.21% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.78M 10-K · filed 2026-03-16 | |||
| 2024-12-31 | $3.47M 10-K · filed 2026-03-16 | |||
| 2023-12-31 | $3.38M 10-K · filed 2026-03-16 | |||
| 2022-12-31 | $3.11M 10-K · filed 2025-03-17 | |||
| 2021-12-31 | $1.83M 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $353.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $878.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.37M derived: sum of 3 quarters · filed 2023-03-16 | $1.89M 10-K · filed 2023-03-16 |
| 2020-09-30 | $525.00K 10-Q · filed 2020-11-09 | $1.02M derived: sum of 2 quarters · filed 2020-11-09 | $1.53M 10-Q · filed 2020-11-09 | $1.88M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $495.00K 10-Q · filed 2020-08-10 | $1.01M 10-Q · filed 2020-08-10 | $1.36M derived: sum of 3 quarters · filed 2022-03-01 | $1.77M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $513.00K 10-Q · filed 2020-05-11 | $861.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.27M derived: sum of 3 quarters · filed 2022-03-01 | $1.63M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $759.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.12M derived: sum of 3 quarters · filed 2022-03-01 | $1.41M 10-K · filed 2022-03-01 |
| 2019-09-30 | $411.00K 10-Q · filed 2020-11-09 | $768.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.07M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $357.00K 10-Q · filed 2020-08-10 | $655.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $161.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |